Skip to main content

17-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The COSMIC-021 mCRPC cohort

Neeraj Agarwal outlines the findings of the metastatic castration-resistant prostate cancer cohort of the COSMIC-021 trial of cabozantinib plus atezolizumab presented as a poster at ASCO GU 2020 (3:21).

Read the transcript

ASCO GU 2020 conference hub

Image Credits